`U.S. Patent No. 7,049,328
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`TARO PHARMACEUTICALS U.S.A., INC.,
`Petitioners,
`
`v.
`
`APOTEX TECHNOLOGIES, INC.,
`Patent Owner.
`________________
`
`Case IPR2017-01446
`U.S. Patent No. 7,049,328
`
`Title: USE FOR DEFERIPRONE
`________________
`
`
`PATENT OWNER’S OBJECTIONS TO EVIDENCE
`PURSUANT TO 37 C.F.R. § 42.64
`
`
`
`Pursuant to 37 C.F.R. § 42.64, Patent Owner Apotex Technologies, Inc.
`
`IPR2017-01446
`U.S. Patent No. 7,049,328
`
`
`(“Apotex”) presents the following objections to evidence served with the Petition
`
`of Taro Pharmaceuticals USA, Inc. (“Taro” or “Petitioner”).
`
`I.
`
`Exhibit 1002
`
`Apotex objects to Exhibit 1002, Declaration of Jayesh Mehta, M.D.
`
`Specifically, Apotex objects to ¶¶ 26-28, 30, 33, 34, 36, 37, 40, 55, 56, 60, 64, 66,
`
`67, 72, 74-76, 80, and 82-85 as not based on sufficient facts or data, the product of
`
`reliable principles and methods, and/or reliable application of the principles of
`
`methods and facts. See Fed. R. Evid. 702, 703, 705, 403; 77 Fed. Reg. at 48,763;
`
`37 C.F.R. § 42.65.
`
`Apotex objects to ¶¶ 31, 34, 37- 40, 63-65, 68-71, and 80-81 as irrelevant.
`
`See Fed. R. Evid. 402. These paragraphs are not directly cited in the Petition and
`
`the relevance of the paragraphs is not apparent. Apotex further objects to ¶ 30 as
`
`irrelevant because it contains a cite to Exhibit 1028, which is not cited in the
`
`Petition. See Fed. R. Evid. 402.
`
`Apotex objects to ¶¶ 63-85 as testimony provided on a topic which the
`
`declarant is not qualified to opine. See Fed. R. Evid. 702 and 703.
`
`Apotex further objects to Ex. 1002, which does not disclose Dr. Mehta’s
`
`compensation. See Ex. 1002 at ¶ 1; Fed. R. Civ. P. 26(a)(2)(B)(vi).
`
`1
`
`
`
`II. Exhibits 1005, 1006, 1022, 1024, 1026, and 1030
`
`
`
`Apotex objects to the relevance of Exhibits 1005, 1006, 1022, 1024, 1026,
`
`and 1030 in the obviousness analysis of the Petition and Dr. Mehta’s obviousness
`
`analysis. See Petition at pp. 43-51; see also Ex. 1002 at ¶ 83. Specifically,
`
`because the Petition failed to identify any combination of references in the
`
`obviousness analysis, the relevance of Exhibits 1005, 1006, 1022, 1024, 1026 and
`
`1030 to the alleged obviousness of the challenged claims of the ’328 patent is not
`
`apparent. See Fed. R. Evid. 402.
`
`III. Exhibits 1028, 1029, 1031, 1033-1035
`
`
`
`Apotex objects to the relevance and probative value of Exhibits 1028, 1029,
`
`1031, and 1033-1035, which are not cited in the Petition. See Fed. R. Evid. 401,
`
`402, and 403.
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: December 12, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
` By: W. Blake Coblentz
`
`W. Blake Coblentz
`
`Reg. No. 57,104
`
`COZEN O’CONNOR
`1200 Nineteenth Street, N.W.
`Washington, D.C. 20036
`(202) 912-4837
`
`
`
`2
`
`
`
`IPR2017-01446
`U.S. Patent No. 7,049,328
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on December 12, 2017, I caused a true and correct copy
`
`of Patent Owner’s Objections to Evidence to be served via electronic mail on the
`
`following attorneys of record:
`
`Huiya Wu
`Sarah Fink
`GOODWIN PROCTER LLP
`The New York Times Building
`620 Eighth Avenue
`New York, NY 10018-1405
`HWu@goodwin.law.com
`SFink@goodwinlaw.com
`
`
`
`
`
`
`
`Date: December 12, 2017
`
`
`
`
`
`
`
`/s/ W. Blake Coblentz
`W. Blake Coblentz
`Reg. No. 57,104
`COZEN O’CONNOR
`1200 Nineteenth Street, N.W.
`Washington, DC 20036
`(202) 912-4837
`
`